Last reviewed · How we verify

Suboxone (SCH 000484) — Competitive Intelligence Brief

Suboxone (SCH 000484) (Suboxone (SCH 000484)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist-antagonist combination. Area: Psychiatry / Addiction Medicine.

marketed Opioid agonist-antagonist combination Mu-opioid receptor (buprenorphine); opioid receptors (naloxone) Psychiatry / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Suboxone (SCH 000484) (Suboxone (SCH 000484)) — Merck Sharp & Dohme LLC. Suboxone is a combination of buprenorphine (a partial opioid agonist) and naloxone (an opioid antagonist) that reduces opioid cravings and withdrawal symptoms while minimizing abuse potential.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Suboxone (SCH 000484) TARGET Suboxone (SCH 000484) Merck Sharp & Dohme LLC marketed Opioid agonist-antagonist combination Mu-opioid receptor (buprenorphine); opioid receptors (naloxone)
Zubsolv sublingual tablets Zubsolv sublingual tablets Indivior Inc. marketed Opioid agonist-antagonist combination Mu-opioid receptor (buprenorphine); opioid receptors (naloxone antagonism)
Buprenorphine, Naloxone Drug Combination Buprenorphine, Naloxone Drug Combination The University of Texas Health Science Center, Houston marketed Opioid agonist-antagonist combination Mu-opioid receptor (buprenorphine as partial agonist; naloxone as antagonist)
Buprenorphine Naloxone Buprenorphine Naloxone Johns Hopkins University marketed Opioid agonist-antagonist combination Mu-opioid receptor (buprenorphine as partial agonist; naloxone as antagonist)
Low Bup/Nal Dose Low Bup/Nal Dose New York State Psychiatric Institute phase 3 Opioid agonist-antagonist combination Mu-opioid receptor (buprenorphine); opioid receptors (naloxone antagonism)
Buprenorphine/naloxone sublingual tablets Buprenorphine/naloxone sublingual tablets Orexo AB phase 3 Opioid agonist-antagonist combination Mu-opioid receptor (buprenorphine partial agonist; naloxone antagonist)
Oxycodone Naltrexone (a) Oxycodone Naltrexone (a) Elite Laboratories, Inc phase 3 Opioid agonist-antagonist combination Mu-opioid receptor (oxycodone agonist); opioid receptors (naltrexone antagonist)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist-antagonist combination class)

  1. New York State Psychiatric Institute · 2 drugs in this class
  2. Elite Laboratories, Inc · 2 drugs in this class
  3. Alkermes, Inc. · 2 drugs in this class
  4. Merck Sharp & Dohme LLC · 1 drug in this class
  5. Orexo AB · 1 drug in this class
  6. The University of Texas Health Science Center, Houston · 1 drug in this class
  7. Indivior Inc. · 1 drug in this class
  8. Johns Hopkins University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Suboxone (SCH 000484) — Competitive Intelligence Brief. https://druglandscape.com/ci/suboxone-sch-000484. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: